Pratiti (Mimi) Bandopadhayay

Graphic for the Disease Models & Mechanisms meeting: “Innovative Preclinical Models for Pediatric Cancer Research”. This is scheduled for 13–15 October 2026 at Nationwide Children’s Hospital Conference Center in Columbus, Ohio, USA. The design includes a green button labeled “Register your interest,” and a microscopy image of fluorescent cells.

We have a fantastic line up of speakers for our 2026 Journal Meeting organised by @amatrudalab.bsky.social, @bandolab.bsky.social, @banitolab.bsky.social and Elaine Mardis @nationwidekids.bsky.social!

🚨Register your interest now so you're first to get updates🚨

www.biologists.com/meetings/dmm...

Daniel Nomura, David McFadden, Kimberly Stegmaier, and Pratiti Bandopadhayay will discuss "Discovery of New Targets With Functional and Chemical Genomics" in a plenary at the AACR Conference on Fusion-Positive Cancers (January 13-15; Philadelphia).
buff.ly/S2biIJv
#AACRfusion26 @bandolab.bsky.social

Scalable Tracking of Symptoms in the Electronic Health Record using Large Language Models in Patients with Central Nervous System Cancers Undergoing Therapy AbstractBackground. Advances in large language models (LLMs) provide a means for scalable tracking of patient symptoms in clinical trials and post-marking

This was a fun project with John Rhee and Charlotta Lindvall on using LLMs to scour medical records. It has been wonderful to work with them!
secure-web.cisco.com/1QgAtJ9SFoCj...

#pediatriccancerawareness | René Marsh Federal funding for a pediatric brain cancer network of top doctors, scientists and hospitals across the country is being cut. Health and Human Services tells CNN the cut is for efficiency. The Pedi...

Everyone needs to watch this. Our children deserve better. They need MORE funding, resources and research. Not less. lnkd.in/gevV3Gth

Pediatric Brain Cancer Group to Lose Federal Funding

www.nytimes.com/2025/08/28/w...

Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely.

The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.

Terrible news for pediatric brain tumor research and incredible amount of hard work wasted. This very likely will result in some active trials prematurely closing without sufficient accrual to answer their aims.

Every dollar invested by the federal government on health research returns $2.60 in economic activity, not to mention the benefits to our health. The federal government spends very little on biomedical research as it is; it is so counterproductive to cut what remains. ☹️

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...

Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG

Excited to be part of the editorial team for the FIRST journal specifically focused on pediatric brain tumors. Submissions now open!

An inspirational (and fun) few days of science at the joint Bando-Beroukhim-Ligon Labs retreat in Maine. Joined by Nada Jabado, Claudia Kleinman and Veronica Rendo. We are all on the mission together to find better treatments for our kids #BandoLab

A fun project with @rameenberoukhim.bsky.social and @vrendo.bsky.social focused on how the interplay between structural variants at the BRD4 locus fine tunes its expression. Congratulations to Jeremiah, Simona, Sophie and team, and also to Veronica! Looking forward to many more collaborations ahead.

Congratulations to @vrendo.bsky.social. Very excited for the amazing science that is still to come from the Rendo Lab for our kids with brain tumors

Research Laboratory Job: Sr Scientist - Bandopadhayay Lab at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA Sr Scientist - Bandopadhayay Lab job

The Bando and Beroukhim Labs (www.bandolab.org, www.beroukhimlab.org) are seeking a Senior Scientist to help find better treatments for children with brain tumors. More details here: careers.dana-farber.org/job/11089/sr...

@rameenberoukhim.bsky.social #BandoLab #DFCI @broadinstitute.org

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma In patients with glioblastoma, navtemadlin resistance is not mediated by TP53-inactivating mutations, and combination with TMZ may improve efficacy.

So excited to see this paper out! An example of how window of opportunity trials can help dissect the mechanisms of response and resistance associated with targeted therapies in glioblastoma 🧠
www.science.org/doi/10.1126/...
Thanks to the patients and scientific team who made this study possible.

With an aim to drive collaborative team science & in honor of our remarkable #CARTcell patients, we started the annual Cleveland Hood Lecture w/ Dr Neev Manoharan of Sydney Children’s Hospital as our inaugural speaker. It’s a privilege to build intercontinental alliances against childhood cancer ❤️🔬

Congratulations to @johnprensner.bsky.social and the entire team!

BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...

Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬

N-terminal modification of Histone H3 inhibits H3K27M-mediated loss of H3K27 trimethylation The use of short epitope tags is widespread in the study of histone H3 biology as they allow for the antibody-mediated detection and pulldown of particular histone post-translational modifications (PT...

Proud to share this preprint on behalf of Nico, Daren and team with some insights that we hope will be helpful to those modeling K27M mutations in histone proteins. #BandoLab

www.biorxiv.org/content/10.1...

mRNA export factors store nascent transcripts within nuclear speckles as an adaptive response to transient global inhibition of transcription Transcription inhibitors also disrupt nuclear export. Here, Williams et al. reveal that mRNA export factors sense transcription inhibition and adapt by storing mature export-competent mRNA in nuclear speckles. This enables rapid release when transcription resumes and ensures retention of cellular identity and viability during a transient global transcription insult.

Why can a human tolerate a drug that globally inhibits transcription? Why do transcription inhibitors not cure cancer? Our first paper of 2025 may help explain (some) of this!

So incredibly proud of @tobiaswilliams.bsky.social & Ewa Michalak who led the work!

www.cell.com/molecular-ce...

A proud mentor moment! Congratulations to Jenna! We are so excited to have you in our team and working for children with brain tumors to find more effective and less toxic treatments.

Www.bandolab.org @broadinstitute.org #DFCI #SNO2024 #ISPNO

Thanks for including me!

#SNO2024…… my first BlueSky meeting! Excited to connect with friends, colleagues and collaborators and brainstorm around our projects focused on pediatric brain tumors. Www.bandolab.org #teamscience #PedBrainTumors #BandoLab #DFCI @broadinstitute.org

We are on this mission together

Ditto back to you and the Prensner Lab!

A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas Alterations in Fibroblast growth factor receptor (FGFR)-family proteins frequently occur as oncogenes in many cancers, including a subset of pediatric gliomas. Here, we performed a genomic analysis of...

Our Blue Skies repost of April and Eric's preprint, on behalf of the www.bandolab.org, Ligon Lab, David Jones, and collaborators, focused on FGFR-alterations in pediatric gliomas. #TeamScience #PedBrainTumors @broadinstitute.bsky.social #DanaFarber @dkfz.bsky.social

www.biorxiv.org/content/10.1...

Bandopadhayay Lab at Dana-Farber Cancer Institute The Bandopadhayay Lab applies genomics to characterize driver alterations that contribute to pediatric brain tumor formation and to develop strategies to therapeutically target them.

Hello to the Blue Sky community! Excited to join on behalf of www.bandolab.org! We are on a mission to find more effective and less toxic treatments for children with brain tumors